US pharma major Bristol Myers Squibb (NYSE: BMY) has presented updated results from the primary analysis of the Phase III COMMANDS trial at the 2023 American Society of Hematology (ASH) Annual Meeting.
The trial is comparing Reblozyl (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS) who may require red blood cell (RBC) transfusions.
"The analysis confirms that Reblozyl demonstrated clinical benefit across subgroups"Epoetin was originally manufactured and marketed by Amgen (Nasdaq: AMGN) under the brand name Epogen. Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has also sold the drug under the name Procrit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze